The nonsense being posted about VRTX being a 'scam' and a '$30 stock' are absurd. The correctors and potentiators work in CF patients, one is marketed already, and ultimately VRTX drugs will dominate this $4 billion market. On top of that, the company will continue to make money in HepC despite no longer being the dominant player, and has enormous opportunities with their advanced clinical candidates in RA and influenza.
VRTX is one of the very best companies in developing ground-breaking drug discovery initiatives and bringing them to market in the entire biotechnology sector.
1. Senior management of developing biotechnology stocks make lower salaries than their pharma/large biotech counterparts, and receive large stock option packages as part of their compensation.
2. Insiders are selling only those options they've chosen to exercise and hold. Unexercised options in the tens or hundreds of thousands remain unaccounted for on insider sales forms. In other words, the sellers have a bunch more VRTX stock in the form of unexercised options.